Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 19/20 | 0.47 |
| ▸ | TACR2 | P21452 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253970 | 0.88 | CNR1 (0.45) | CNR1TACR2CNR2 | |
| SCHEMBL4242266 | 0.80 | CNR1 (0.73) | CNR1 | |
| SCHEMBL4248289 | 0.73 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL2703667 | 0.65 | CNR1 (0.70) | CNR1TACR2CNR2 | |
| SCHEMBL2487328 | 0.65 | CNR1 (0.75) | CNR1TACR2CNR2 | |
| SCHEMBL4805584 | 0.64 | CNR1 (0.48) | CNR1 | |
| SCHEMBL1377250 | 0.64 | CNR1 (1.00) | CNR1TACR2CNR2 | |
| SCHEMBL5271693 | 0.64 | CNR1 (1.00) | CNR1TACR2CNR2 | |
| SCHEMBL1376708 | 0.64 | CNR1 (1.00) | CNR1TACR2CNR2 | |
| SCHEMBL1377255 | 0.64 | CNR1 (1.00) | CNR1TACR2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | claimed |
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| EP-1910304-A2 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010222-A2 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156616-A1 | THERAPEUTIC AGENTS | NLN, BDNF, GAP43 | CNR1 173/4885TACR2 184/4885CNR2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.